• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

脓毒症患者持续血液滤过期间细胞因子的清除

Cytokine removal during continuous hemofiltration in septic patients.

作者信息

De Vriese A S, Colardyn F A, Philippé J J, Vanholder R C, De Sutter J H, Lameire N H

机构信息

Renal Division of the Department of Medicine, University Hospital, Gent, Belgium.

出版信息

J Am Soc Nephrol. 1999 Apr;10(4):846-53. doi: 10.1681/ASN.V104846.

DOI:10.1681/ASN.V104846
PMID:10203370
Abstract

A potential application of the continuous renal replacement therapies is the extracorporeal removal of inflammatory mediators in septic patients. Cytokine elimination with continuous renal replacement therapies has been demonstrated in several clinical studies, but so far without important effects on their serum concentrations. Improved knowledge of the cytokine removal mechanisms could lead to the development of more efficient treatment strategies. In the present study, 15 patients with septic shock and acute renal failure were observed during the first 24 h of treatment with continuous venovenous hemofiltration (CVVH) with an AN69 membrane. After 12 h, the hemofilter was replaced and the blood flow rate (QB) was switched from 100 ml/min to 200 ml/min or vice versa. Pre- and postfilter plasma and ultrafiltrate concentrations of selected inflammatory and anti-inflammatory cytokines were measured at several time points allowing the calculation of a mass balance. Cytokine removal was highest 1 h after the start of CVVH and after the change of the membrane (ranging from 25 to 43% of the prefilter amount), corresponding with a significant fall in the serum concentration of all cytokines. The inhibitors of inflammation were removed to the same extent as the inflammatory cytokines. Adsorption to the AN69 membrane appeared to be the main clearance mechanism, being most pronounced immediately after installation of a new membrane and decreasing steadily thereafter, indicating rapid saturation of the membrane. A QB of 200 ml/min was associated with a 75% increase of the ultrafiltration rate and a significantly higher convective elimination and membrane adsorption than at a QB of 100 ml/min. The results indicate that optimal cytokine removal with CVVH with an AN69 membrane could be achieved with a combination of a high QB/ultrafiltration rate and frequent membrane changes.

摘要

持续肾脏替代疗法的一个潜在应用是体外清除脓毒症患者体内的炎症介质。多项临床研究已证实持续肾脏替代疗法可清除细胞因子,但迄今为止,对其血清浓度并无显著影响。深入了解细胞因子清除机制可能会促使开发出更有效的治疗策略。在本研究中,对15例脓毒症休克合并急性肾衰竭患者在使用AN69膜进行持续静静脉血液滤过(CVVH)治疗的最初24小时内进行了观察。12小时后,更换血液滤过器,将血流速度(QB)从100毫升/分钟切换至200毫升/分钟,或反之。在多个时间点测量滤器前后血浆及超滤液中选定的炎性和抗炎细胞因子浓度,以便计算质量平衡。细胞因子清除在CVVH开始后1小时以及更换滤膜后最高(为滤器前量的25%至43%),这与所有细胞因子血清浓度的显著下降相对应。炎症抑制剂的清除程度与炎性细胞因子相同。吸附至AN69膜似乎是主要的清除机制,在安装新膜后立即最为明显,此后逐渐下降,表明膜迅速饱和。200毫升/分钟的QB与超滤率增加75%相关,且与100毫升/分钟的QB相比,对流清除和膜吸附显著更高。结果表明,结合高QB/超滤率和频繁更换滤膜可实现使用AN69膜的CVVH对细胞因子的最佳清除。

相似文献

1
Cytokine removal during continuous hemofiltration in septic patients.脓毒症患者持续血液滤过期间细胞因子的清除
J Am Soc Nephrol. 1999 Apr;10(4):846-53. doi: 10.1681/ASN.V104846.
2
Cytokine removal and cardiovascular hemodynamics in septic patients with continuous venovenous hemofiltration.连续性静脉-静脉血液滤过对脓毒症患者细胞因子清除及心血管血流动力学的影响
Intensive Care Med. 1997 Mar;23(3):288-96. doi: 10.1007/s001340050330.
3
Mass transfer, clearance and plasma concentration of procalcitonin during continuous venovenous hemofiltration in patients with septic shock and acute oliguric renal failure.脓毒性休克合并急性少尿性肾衰竭患者持续静静脉血液滤过期间降钙素原的物质转运、清除率及血浆浓度
Crit Care. 2003 Dec;7(6):R160-6. doi: 10.1186/cc2372. Epub 2003 Oct 2.
4
Myoglobin clearance and removal during continuous venovenous hemofiltration.持续静脉-静脉血液滤过过程中肌红蛋白的清除与去除
Intensive Care Med. 1999 Oct;25(10):1169-72. doi: 10.1007/s001340051031.
5
Effectiveness of High Cut-Off Hemofilters in the Removal of Selected Cytokines in Patients During Septic Shock Accompanied by Acute Kidney Injury-Preliminary Study.高截留量血液滤过器对伴有急性肾损伤的感染性休克患者特定细胞因子的清除效果——初步研究
Med Sci Monit. 2016 Nov 13;22:4338-4344. doi: 10.12659/MSM.896819.
6
First successful combination of ECMO with cytokine removal therapy in cardiogenic septic shock: a case report.体外膜肺氧合(ECMO)与细胞因子清除疗法在心源性脓毒性休克中的首次成功联合应用:一例病例报告
Int J Artif Organs. 2015 Feb;38(2):113-6. doi: 10.5301/ijao.5000382. Epub 2015 Feb 3.
7
Comparison of polyacrylonitrile (AN69) and polysulphone membrane during hemofiltration in canine endotoxic shock.犬内毒素性休克血液滤过期间聚丙烯腈(AN69)膜与聚砜膜的比较。
Crit Care Med. 2003 Apr;31(4):1219-25. doi: 10.1097/01.CCM.0000060446.45080.C6.
8
A pilot study of high-adsorption hemofiltration in human septic shock.高吸附血液滤过治疗人感染性休克的一项初步研究。
Int J Artif Organs. 2007 Feb;30(2):108-17. doi: 10.1177/039139880703000205.
9
Continuous veno-venous hemofiltration improves hemodynamics in septic shock with acute renal failure without modifying TNFalpha and IL6 plasma concentrations.持续静脉-静脉血液滤过可改善伴有急性肾衰竭的感染性休克患者的血流动力学,而不改变血浆肿瘤坏死因子α和白细胞介素6的浓度。
J Nephrol. 2002 Mar-Apr;15(2):150-7.
10
Blood and plasma treatments: the rationale of high-volume hemofiltration.血液和血浆治疗:高容量血液滤过的基本原理。
Contrib Nephrol. 2007;156:387-95. doi: 10.1159/000102129.

引用本文的文献

1
Immunomodulation in Pediatric Sepsis: A Narrative Review.儿童脓毒症中的免疫调节:一篇叙述性综述
J Clin Med. 2025 Apr 25;14(9):2983. doi: 10.3390/jcm14092983.
2
Hemoperfusion Using the Oxiris Membrane in Septic Shock Patients with Preserved Kidney Function: A Case Series.在肾功能正常的脓毒症休克患者中使用奥西里斯膜进行血液灌流:病例系列
J Clin Med. 2025 Mar 19;14(6):2113. doi: 10.3390/jcm14062113.
3
Comparison of Different Membranes for Continuous Renal Replacement Therapies: An In Vitro Study.不同膜用于连续性肾脏替代治疗的比较:一项体外研究
ASAIO J. 2025 Jun 1;71(6):510-518. doi: 10.1097/MAT.0000000000002387. Epub 2025 Feb 5.
4
Nanolevel Immunomodulators in Sepsis: Novel Roles, Current Perspectives, and Future Directions.脓毒症中的纳米级免疫调节剂:新作用、当前观点和未来方向。
Int J Nanomedicine. 2024 Nov 23;19:12529-12556. doi: 10.2147/IJN.S496456. eCollection 2024.
5
Effects of Oxiris Therapy on Cytokine Elimination after a LPS Infusion-An Experimental Animal Study.奥西里斯疗法对 LPS 输注后细胞因子消除的影响——一项实验动物研究。
Int J Mol Sci. 2024 Aug 27;25(17):9283. doi: 10.3390/ijms25179283.
6
High-volume hemofiltration does not protect human kidney endothelial and tubular epithelial cells from septic plasma-induced injury.高容量血液滤过不能保护人肾内皮和肾小管上皮细胞免受脓毒性血浆引起的损伤。
Sci Rep. 2024 Aug 7;14(1):18323. doi: 10.1038/s41598-024-69202-z.
7
Survival benefit of resin cartridge extracorporeal blood purification therapy in patients with septic shock.树脂筒式体外血液净化疗法对感染性休克患者的生存获益。
Turk J Med Sci. 2023 Nov 11;54(1):128-135. doi: 10.55730/1300-0144.5773. eCollection 2024.
8
Clinical analysis of AN69ST membrane continuous venous hemofiltration in the treatment of severe sepsis.AN69ST膜连续性静脉血液滤过治疗严重脓毒症的临床分析
Open Med (Wars). 2023 Sep 12;18(1):20230784. doi: 10.1515/med-2023-0784. eCollection 2023.
9
Effects of Tocilizumab on Inflammation and Iron Metabolism in Critically Ill Patients with COVID-19.托珠单抗对COVID-19危重症患者炎症及铁代谢的影响
Pharmaceutics. 2023 Feb 14;15(2):646. doi: 10.3390/pharmaceutics15020646.
10
Timely renal replacement therapy linked to better outcome in patients with sepsis-associated acute kidney injury.及时的肾脏替代治疗与脓毒症相关急性肾损伤患者更好的预后相关。
J Intensive Med. 2022 Jun 1;2(3):173-182. doi: 10.1016/j.jointm.2022.03.004. eCollection 2022 Jul.